At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 275 enrolled
Drug / intervention
Pembrolizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Renal Cell Carcinoma. Completed, enrolled 275 participants.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC). There will be two cohorts in this study: Cohort A will consist of participants with clear cell (cc) RCC and Cohort B will consist of participants with non-clear cell (ncc) RCC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartSep 2016
Primary CompletionFeb 2021
Study CompletionApr 2022
TodayJul 2026
First PostedAug 2, 2016
Enrollment StartSep 30, 2016
Primary CompletionFeb 5, 2021
Study CompletionApr 1, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.9 years ago
Interventions
Pembrolizumabbiological
IV infusion